Moderna, Inc. — Director's Dealing 2020

Sep 29, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-09-28

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-28	Common Stock	M	7197	$20.93	Acquired	7197	Direct
2020-09-28	Common Stock	M	10000	$19.15	Acquired	17197	Direct
2020-09-28	Common Stock	S	7019	$69.75	Disposed	10178	Direct
2020-09-28	Common Stock	S	10178	$70.64	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-28	Stock Option (Right to Buy)	$20.93	M	7197	Disposed	2029-03-08	Common Stock (7197)	Direct
2020-09-28	Stock Option (Right to Buy)	$19.15	M	10000	Disposed	2026-08-10	Common Stock (10000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.19 to $70.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.21 to $71.21. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: This option is fully vested and exercisable.